# Participant Journey

For study participants: This tool is to help you understand what to expect during the Oasis study.

1.

### Review and sign the Informed Consent Form (ICF) and Assent Form

Before you receive any study drug or assessments, the study doctor will review the ICF or, if you are under age 18, the Assent Form. The ICF will explain the risks and benefits of your participation in the Oasis study.

2.

### Find out if you qualify (Screening Period)

During the Screening Period, you will receive health assessments and be monitored to confirm you qualify for the study. This period may last up to 8 weeks.

3.

### Receive first injection of study drug or placebo

You will visit the study clinic and be randomly assigned to receive injections of the study drug or placebo. You are 3 times as likely to receive the study drug.

4.

### Complete the Study Treatment Period

Visit the study clinic once every 4 weeks for 25 weeks (almost 6 months) to continue receiving injections and health assessments. Some visits may take place at home.

5a.

### Complete the Follow-up Period

You will attend 3 study visits in 13 weeks (a little over 3 months) for follow-up assessments.

5b.

### Optional: Participate in an open-label study

You may be eligible to join an optional, long-term extension study and receive the study drug (no placebo).

# Participant Journey

For site staff: Use these talking points to review the study with potential study participants.

## 1. Review and sign the Informed Consent Form (ICF) and Assent Form

- The Informed Consent Form (ICF) and Assent Form explain the study and what participants can expect in more detail.
- The ICF will explain the risks and benefits of your participation in the Oasis study and everything that is currently known about the benefits and risks of the study drug. If you have questions about the ICF, you can ask the study team.
- The ICF must be signed by you if you are 18 years of age or older, and by a parent or legal guardian if you are younger than 18. You must sign the Assent Form if you are younger than 18 years old.
- You can take these forms home to discuss the information with friends and family before you decide to participate. Participating in this study is completely voluntary, but you or your legal representative must sign the ICF (in other words, give consent) before you receive any study drug or assessments.

## 2. Find out if you qualify (Screening Period)

- You will receive health assessments and be monitored to confirm you meet the study requirements. This process is called the Screening Period.
- Assessments include a physical exam, blood and urine tests, a heart test, and a review of your HAE history. You also must experience at least 2 HAE attacks during an 8-week period in order to qualify for the study.

## 3. Receive first injection of study drug or placebo

- If you meet all study requirements, you will be randomly assigned to receive injections of either the study drug or placebo. Placebo looks like the study drug, but it does not have any active ingredients. Neither you nor the study doctor will know your assignment. You are 3 times as likely to be assigned to the study drug.
- Depending on the group you are assigned to, you will receive a total of either 3 or 6 injections during the study. Neither you nor the study doctor will be able to pick how many injections you receive.
- These injections are done during study clinic visits.

## 4. Complete the Study Treatment Period

- After the first study visit, you will visit the study clinic 6 more times (about once every 4 weeks) for health assessments and to receive injections of the study drug or placebo. Assessments will be similar to those received during the Screening Period.
- In between study visits, you will complete daily questionnaires about your HAE symptoms. You will also be expected to report any HAE attacks to the study team. A member of the study team will call you every week in between study visits to ask about recent HAE attacks.
- You may be able to complete some study visits at home. The study team can provide more information about home healthcare options.

## 5a. Complete the Follow-up Period

- After your Week 25 visit during the Study Treatment Period, you will begin the Follow-up Period. During this time, you will attend 3 study clinic visits in 13 weeks (a little over 3 months). At each visit, you will receive assessments that help the study team check your health and make sure you are safe. These assessments will be similar to others received throughout the study.

## 5b. Optional: Participate in an open-label study

- When you complete the Study Treatment Period, you may be eligible to participate in an open-label extension study. If you decide to join this study, you will receive injections of the study drug (no placebo). The study team can provide more information about this option.
- If you decide to join the open-label extension study, you may not need to complete some or all of the Follow-up Period visits during the Oasis study.